Recipharm to expand its facility in Solna, Sweden
Adding capacity in analytical services and stability studies
Swedish contract development and manufacturing organisation Recipharm is to invest an undisclosed sum in expanding its capacity in analytical services and stability studies at its facility in Solna, Sweden.
The plant is equipped with advanced laboratories and technology for pharmaceutical formulation as well as a GMP suite for development and manufacturing of sterile and non-sterile clinical trial materials.
The plant will be reconstructed to facilitate the expansion and will be ready and fully compliant with ICH, EU and FDA GMP by May next year.
‘This is a very important step for us as increasing this capacity will enable the company to enhance the high quality services to our customers,’ said Maria Lundberg, general manager at Recipharm Pharmaceutical Development.
‘Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering.’
Analytical services included in the pharmaceutical offering comprise: development and validation of stability indicating analytical methods, supply and execution of method transfer protocols, establishment of new product assay and degradation methods, graduated validation plans to suit the phase of drug development, cleaning validation, report writing and stability studies according to ICH.
Recipharm says this expansion will mean that it will have the capability to support more projects in parallel with these services.
